Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865652 | 1.00 | CAPN1 (0.61) | CAPN1ACECTSB | |
| SCHEMBL3292711 | 1.00 | CAPN1 (0.61) | CAPN1ACECTSB | |
| SCHEMBL16932220 | 0.90 | CAPN1 (0.52) | CAPN1ACECTSB | |
| SCHEMBL20204724 | 0.87 | CTSB (0.55) | CAPN1ACECTSB | |
| SCHEMBL20204721 | 0.87 | CTSB (0.55) | CAPN1ACECTSB | |
| SCHEMBL2293365 | 0.86 | CAPN1 (0.53) | CAPN1CTSB | |
| SCHEMBL10045690 | 0.86 | CAPN1 (0.58) | CAPN1ACECTSB | |
| SCHEMBL2911854 | 0.86 | CAPN1 (0.58) | CAPN1ACECTSB | |
| SCHEMBL12125815 | 0.86 | CAPN1 (0.58) | CAPN1ACECTSB | |
| SCHEMBL2269431 | 0.86 | CAPN1 (0.58) | CAPN1ACECTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895492-A1 | PROCESS FOR PREPARING OF BORTEZOMIB | Cipla Limited (IN) | 2015-07-22 | — | — | EP | claimed |
| WO-2014041324-A1 | PROCESS FOR PREPARING OF BORTEZAMIB | CIPLA LIMITED (IN) | 2014-03-20 | — | — | WO | claimed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3788031-B1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED S L (ES) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022192562-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | LANDSTEINER GENMED, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2021-10-14 | — | — | US | disclosed |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2137139-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | Clariant Specialty Fine Chemicals (France) (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008125486-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-10-23 | — | — | WO | disclosed |
| US-5583248-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5294720-A | Viricides | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5135914-A | Controlling hypertension, hyperaldosteronism, and congestive heart failure | WARNER-LAMBERT COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1991018866-A2 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | ALDH7A1, AADAT, AASDHPPT | CAPN1 1431/4885ACE 85/4885CTSB 1587/4885 |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | DPP4, DPP7, DPP3 | CAPN1 25/4885ACE 9/4885CTSB 159/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | CAPN1 4685/4885ACE 1795/4885CTSB 1930/4885 |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | DPP4, DPP7, DPP3 | CAPN1 25/4885ACE 9/4885CTSB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.